U.S. markets closed
  • S&P Futures

    4,118.50
    -8.00 (-0.19%)
     
  • Dow Futures

    33,666.00
    -37.00 (-0.11%)
     
  • Nasdaq Futures

    13,735.50
    -58.75 (-0.43%)
     
  • Russell 2000 Futures

    2,181.40
    -2.60 (-0.12%)
     
  • Crude Oil

    62.61
    +0.17 (+0.27%)
     
  • Gold

    1,784.40
    +6.00 (+0.34%)
     
  • Silver

    25.99
    +0.15 (+0.56%)
     
  • EUR/USD

    1.2035
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • Vix

    18.68
    +1.39 (+8.04%)
     
  • GBP/USD

    1.3930
    -0.0007 (-0.05%)
     
  • USD/JPY

    107.9690
    -0.1010 (-0.09%)
     
  • BTC-USD

    55,735.96
    +986.01 (+1.80%)
     
  • CMC Crypto 200

    1,277.40
    +42.98 (+3.48%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    28,462.20
    -638.18 (-2.19%)
     

Merck warns against using anti-parasite drug to treat COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Feb 4 (Reuters) - Drugmaker Merck & Co Inc on Thursday said its analysis of available data does not support the safety and efficacy of its anti-parasite drug, ivermectin, for the treatment of COVID-19.

Ivermectin, which is approved in the United States under the brand name Stromectol, is used mainly to treat roundworms, threadworms and other parasites.

Officials in the Bolivian city of Trinidad had launched a campaign in May last year to give out free doses of ivermectin to combat the novel coronavirus, although the South American country's health ministry noted the lack of evidence for it as a treatment for COVID-19. (https://reut.rs/3oVnHsY) The company said its analysis of existing and emerging studies of ivermectin to treat COVID-19 found no scientific basis for a potential therapeutic effect against the respiratory disease caused by the novel coronavirus. (https://bit.ly/2Mz1NOW)

Merck added that there was a concerning lack of safety data in the majority of studies testing ivermectin to treat COVID-19 and cautioned against the use of the drug beyond its use as an anti-parasitic. (Reporting by Amruta Khandekar; Editing by Ramakrishnan M.)